ID | 64370 |
JaLCDOI | |
フルテキストURL | |
著者 |
Higuchi, Chigusa
Health Service Center, Okayama University
|
抄録 | The inactivated coronavirus disease 2019 vaccine CoronaVac has not been approved in Japan. Little information is available on cases in Japan in which an approved mRNA vaccine was administered as the initial (first or second) dose after two doses of CoronaVac. Furthermore, the safety and efficacy of this combination are not established. We here evaluated the safety and efficacy in a patient who showed an antibody response to an approved vaccine, mRNA-1273, after a previous vaccination with CoronaVac. The adverse events consisted of only mild local and systemic common reactions and were transient. In addition, a strong and persistent antibody response was observed.
|
キーワード | coronavirus disease 2019
severe acute respiratory syndrome coronavirus 2
vaccine
adverse events
antibody response
|
Amo Type | Case Report
|
出版物タイトル |
Acta Medica Okayama
|
発行日 | 2023-02
|
巻 | 77巻
|
号 | 1号
|
出版者 | Okayama University Medical School
|
開始ページ | 105
|
終了ページ | 109
|
ISSN | 0386-300X
|
NCID | AA00508441
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
著作権者 | Copyright Ⓒ 2023 by Okayama University Medical School
|
論文のバージョン | publisher
|
査読 |
有り
|
PubMed ID | |
Web of Science KeyUT |